Menu

Markets

Research

News

Learn
Paper trading
AI Chat
Get the app WatchlistsPortfoliosAlerts
Sign in

Phathom Pharmaceuticals, Inc. PHAT

Set alert

Price alert · PHAT

All alert types
5.92 USD +0.17 +3.05%

At close · Nov 2

5.92 0.00 0.00%

After hours · Nov 2, 4:00 PM ET

Bid
5.91 × 1
Ask
5.92 × 2
5.50 Day range 5.93
5.02 52-week range 18.31
YTD
-64.35%
1 year
-56.35%
Open
5.76
Prev close
5.74
Mkt cap
480.84M
Vol
2.81M
Avg vol
1.43M
EPS
-1.01
P/E
0.00
Div yield
0.00%
More statistics
Low
5.50
High
5.93
Forward P/E
7.60
Beta
0.61
Short ratio
9.36
Inst. own
83.10%
Dividend
0.00
Ex-div date
50-d avg
11.63
200-d avg
12.45
1y target
23.70

6M chart

Chart tools
Interval
1m5m15m30m

Signals (28)
NameDateAgo
MACD: Sell SignalOct 23, 20261 week ago
RSI: OversoldOct 23, 20261 week ago
MACD: Buy SignalOct 8, 20263 weeks ago
MACD: Sell SignalSep 11, 20261 month ago
MACD: Buy SignalAug 14, 20262 months ago
RSI: OversoldAug 5, 20262 months ago
SMA: BearishJul 30, 20263 months ago
SMA: BearishJul 30, 20263 months ago
MACD: Sell SignalJul 30, 20263 months ago
MACD: Buy SignalJul 23, 20263 months ago
SMA: BullishJul 22, 20263 months ago
SMA: BullishJul 21, 20263 months ago
MACD: Sell SignalJul 16, 20263 months ago
SMA: BearishJul 13, 20263 months ago
SMA: BearishJul 13, 20263 months ago
SMA: BullishJul 6, 20263 months ago
SMA: BullishJul 2, 20264 months ago
MACD: Buy SignalJun 12, 20264 months ago
RSI: OversoldJun 1, 20265 months ago
SMA: BearishMay 21, 20265 months ago

Newest 20 of 28.

Analyst view

Consensus: strong buy

Strong buy
Price target (mean) 23.70 +300.7% upside
Target (low)
13.00
Target (mean)
23.70
Target (high)
29.00
Ratings (0m) 11 10 buy · 1 hold · 0 sell
  • Strong buy2
  • Buy8
  • Hold1
  • Sell0
  • Strong sell0

Recommendation trend

  • This month 11
  • 1 month ago 11
  • 2 months ago 11
  • 3 months ago 11

Earnings and revenue estimates

Consensus for the coming quarters and fiscal years

PHAT analyst estimates
PeriodEPS estimateLow – highYear agoEPS growthRevenue estimateRevenue growthAnalysts
Current quarter-0.1954-0.24 – -0.17-1.07+81.7%58.63M+105.6%5
Next quarter-0.0794-0.13 – -0.04-0.79+89.9%74.59M+88.8%5
Current year0.01275-0.18 – 0.28-2.06+100.6%332.04M+89.6%4
Next year1.541.11 – 2.250.01275+12011.4%528.17M+59.1%5

Upgrades and downgrades

The latest rating changes

PHAT analyst upgrades and downgrades
DateFirmActionFromTo
Mar 27, 2026BarclaysUpgradeEqual-WeightOverweight
Feb 27, 2026GuggenheimMaintainedBuyBuy
Dec 9, 2025BarclaysInitiated—Equal-Weight
Oct 31, 2025HC Wainwright & Co.MaintainedBuyBuy
Jun 9, 2025Craig-HallumMaintainedBuyBuy
Jun 9, 2025HC Wainwright & Co.ReiteratedBuyBuy
Jun 6, 2025NeedhamMaintainedBuyBuy
May 2, 2025Goldman SachsMaintainedNeutralNeutral
May 2, 2025GuggenheimMaintainedBuyBuy
May 2, 2025HC Wainwright & Co.MaintainedBuyBuy
May 2, 2025Craig-HallumMaintainedBuyBuy
Apr 21, 2025NeedhamReiteratedBuyBuy
Apr 17, 2025Goldman SachsMaintainedNeutralNeutral
Apr 9, 2025NeedhamReiteratedBuyBuy
Apr 2, 2025GuggenheimReiteratedBuyBuy
Apr 2, 2025NeedhamReiteratedBuyBuy
Mar 10, 2025Goldman SachsMaintainedNeutralNeutral
Mar 7, 2025HC Wainwright & Co.ReiteratedBuyBuy
Mar 6, 2025NeedhamReiteratedBuyBuy
Jan 10, 2025NeedhamReiteratedBuyBuy
Dec 12, 2024HC Wainwright & Co.ReiteratedBuyBuy
Dec 11, 2024NeedhamReiteratedBuyBuy
Sep 13, 2024NeedhamReiteratedBuyBuy
Sep 6, 2024NeedhamReiteratedBuyBuy
Aug 30, 2024NeedhamReiteratedBuyBuy
Aug 23, 2024NeedhamReiteratedBuyBuy
Aug 19, 2024NeedhamReiteratedBuyBuy
Aug 12, 2024HC Wainwright & Co.ReiteratedBuyBuy
Aug 12, 2024NeedhamReiteratedBuyBuy
Aug 9, 2024Goldman SachsMaintainedNeutralNeutral